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Introduction
Short Tandem Repeats (STRs) represent highly
polymorphic microsatellite markers in human genome
that have tandemly repetitive sequence elements of 2-
7 bps length, located approximately every 10-15 kbs.
Genetic instability is reflected in alterations in the pat-
terns of these polymorphic repeat segments and is
thought to occur when there has been a damage to the
cell mismatch repair (MMR). Examination of loss of
heterozygosity (allelic loss, LOH) using the specific
microsatellite markers is a method of choice in assess-
ing tumour suppressor genes (TSGs) localisation in
human genome. This loss of normal allele in heterozy-
gotic locus, may result from different mechanisms,
including chromosomal deletion, mitotic recombina-
tion (MR), gene conversion, point mutation, or intra-
genic allele inactivation [1]. Consequently, the locus
may become homozygous due to mitotic recombina-
tion, gene conversion or chromosome loss with redu-
plication; hemizygous due to deletion or chromosome
loss, complex heterozygote due to introduction of
another point mutation at the locus, or may remain het-
erozygous (with relation to nucleotide sequence), if
one allele is inactivated intragenically [2]. Typically,
LOH analysis involves comparison of allelic profiles
of microsatellite markers generated by amplification
of DNA from matching normal and tumor samples. An
implementation of commercially available multiplex
PCR kits and automated fluorescence based DNA
detection technology allow increased sensitivity,
unmatched accuracy and high throughput of samples
for forensic casework analysis and kinship tests [3,4].
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Fig. 2. Electrophoregram of LOH at locus D16S539. The upper panel – allelic ladder (Sample 1); middle panel – reference blood DNA
showing a profile of alleles 12 and 13 (Sample 11). The lower panel – liposarcoma DNA showing complete loss of allele 13 (Sample 12).
Fig. 1. Electrophoregram of pLOH at locus vWA. Upper panel – allelic ladder (Sample 1); lower panel – reference blood DNA showing
a profile of alleles 17 and 18 (Sample 18); middle panel – larynx carcinoma DNA showing partial loss of allele 17 (Sample 1).
Multiplex AmpFlSTR Identifiler PCR Amplification
Kit (Applied Biosystems) has been validated to pro-
duce rapid and robust amplification of multiple DNA
loci from biological samples [5]. Amplification of
microsatellite markers will yield one or two major
allele peaks, depending upon whether the individual is
homozygous or heterozygous for that marker. Loss of
an allele in the tumor sample that is found in the cor-
responding normal sample indicates LOH. High inci-
dence of LOH is regarded as a unfavourable prognos-
tic factor, accompanying aggressive nature of the
tumour and indicates involvement of certain genome
regions in cancerogenesis. Genetic establishment of
paternity in deficient cases, the identity of unknown
human corpses or remains is usually based on compar-
isons with DNA profiles obtained from reference sam-
ples collected from female or male relatives. When no
such samples are available a direct comparison with
genetic data of DNA derived from personal items can
be efficient, assuming sufficient quantities of DNA can
be recovered from a personal effect and its sole use by
the victim can be assured. Use of histolopathogical tis-
sue sections as a source for DNA may be necessary in
such cases as well as if mix-up of tissue specimens or
medical malpractice is suspected. Due to increasing
incidence of tumours, according to the Polish National
Cancer Registry, availability of histolopathogical tis-
sue is consequently higher. A significant part of this
archived material includes solid tumors known to
retain genetic alterations in defined genes but also in
repetitive sequences of non-coding DNA regions.
Therefore, alterations of STRs used in forensic case-
work are also possible. In this view, loss of heterozy-
gosity (LOH) and microsatellite instability (MSI) are
the most important characteristics of many tumors [6].
The aim of the study was assessment of possible
effects of LOH at tetranucleotide STR loci in four dif-
ferent tumor types on human genetic identification.
Material and methods
Sample material. The study material comprised the following
tumour specimens: larynx carcinoma from 45 patients treated at
the Otolaryngological Department, Medical University of Bia-
lystok, uveal melanoma from 16 patients treated at the Ophthal-
mological Department, Medical University of Bialystok, cervical
carcinoma from 20 patients and sarcoma from 20 patients treated
at the Regional Center of Oncology in Bialystok. The specimens
were collected during surgical procedures and verified histopatho-
logically. Reference blood samples were collected from all the
patients. The material was stored at -20°C until examination. 
Genetic analysis. Standard organic procedure was used for DNA
extraction with additional microcolumn purification (QIAquick,
Qiagen) when necessary. Fluorescent multiplex PCR was used
according to the manufacturer's recommendations to amplify 15
tetranucleotide-repeat microsatellite loci contained in the commer-
cially available AmpFlSTR Identifiler PCR Amplification Kit
(Applied Biosystems) (Table 1). The research panel includes 13
STRs that constitute the STR standardization project – CODIS
announced in 1997 by the FBI and adopted afterward by forensic
DNA analysts worldwide [7]. Genotyping was performed in a 310
ABI Prism Genetic Analyzer (Applied Biosystems) using GeneS-
can v3.7 and Genotyper v3.7 software. The analyses were per-
formed twice for reproducibility. LOH was defined as a decrease
(at least 50%) in peak height of an allele compared with that of the
other determined after comparison of normal and pathologic DNA.
Statistical analysis. Frequency of LOH was calculated for respec-
tive samples. Statistical comparisons were carried out using Fish-
er's exact test with SPSS software package v.11.0 (SPSS Inc.,
Chicago, USA). P-values of 0.05 or less were considered as statis-
tically significant.
Results
Forty-two percent of the 101 cancer cases analysed
were found to possess alterations of the microsatellites
manifesting with allelic loss. Partial or complete loss
of one allele (pLOH or LOH) could be observed in our
tumour samples (Fig. 1 and Fig. 2). The most fre-
quently altered loci were D3S1358 and D18S51.
Distribution of LOH incidence over the fifteen STR
loci in all investigated cancer types is displayed in
Table 2. The alteration was detected in 47% of cases
with larynx carcinoma: 1 patient (2%) displayed LOH
at 5 loci, 4 patients (9%) at 4 loci, 7 patients (16%) at
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Table 1. Marker characteristics
3 loci, 4 patients (9%) at 2 loci, 5 patients (11%) at 1
locus. Allelic loss frequency was statistically signifi-
cant in high G grade cancers (P=0.0032). The highest
LOH frequency was found in the tumor cases where
the neighbouring cervical lymph nodes were affected
(P=0.0041). LOH was found in 44% of cases with
uveal melanoma: 1 patient (6%) displayed LOH at 3
loci, 2 patients (13%) at 2 loci, 4 patients (25%) at 1
locus. LOH was detected in 60% of cases with cervi-
cal cancers: 3 patients (15%) displayed LOH at 3 loci,
4 patients (20%) at 2 loci, 5 patients (25%) at 1 locus.
In all cases with poor prognostic histopathologic factor
(G3) the alteration was present in all three loci
(P=0.0084). Allelic loss was detected at D8S1179 and
D16S539 in one case of liposarcoma G3 and at
D18S51 in one case od neurofibrosarcoma. No LOH
was found in liposarcoma G1, dermatofibrosarcoma
and cystosarcoma protuberans in either primary or
recurrent tumours. In benign tumours (lipoma and
fibroma) LOH was also absent. 
Discussion
Application of microsatellite loci as forensic genetic
markers is common due to their abundance in the
genome, extreme polymorphism and amplification by
the PCR reaction [8,9]. STR markers can be also used to
detect a change in length of a microsatellite allele result-
ing from either insertion or deletion of repeat units dur-
ing DNA replication and failure of the DNA mismatch
repair system to correct these errors referred to as
microsatellite instability (MSI) [10,11]. Involvement of
certain genome regions in cancerogenesis may result in
LOH/MSI genotype at a locus of interest displaying
allelic drop-out and/or multiple allele peaks [12,13].
Contrary to quasimonomorphic mononucleotide repeat
markers, polymorphic tetranucleotide repeat markers
used in our study are reported to be less sensitive and
specific to MSI alterations in tumor samples with mis-
match repair defects [14,15]. Nonetheless, the use of
tumor tissue for forensic applications is questionable. In
the present study LOH was found in 21 out of 45 cases
(47%) of larynx carcinoma. Our findings are in contrast
with those of El-Naggar et al. who reported LOH in
87% of patients suffering from head and neck squamous
cell carcinoma [16]. According to these authors, in non-
invasive cancers LOH was observed on chromosomes
9p, 9q, 11q, 17p, 18p, while in invasive cancers on chro-
mosomes 3p, 8p, 9p, 9q, 11q. Obviously, our goal
involved the system of loci accepted commonly for
human forensic identification [17] that did not match
exactly the research panel used by the latter authors. It
should be pointed however, that in the both studies com-
parable results were obtained for LOH incidence on
chromosomes 3p and 18q. Also Veltman et al. reported
LOH at 18q21 in pre-malignant laryngeal lesions,
which suggest involvement of this chromosomal region
in the laryngeal carcinogenesis [18]. Malignant uveal
melanoma was documented by Metzelaar-Blok et al. to
display recurring abnormalities particularly on chromo-
some 6q [19]. In contrast to the frequency of 6q loss,
other authors observed LOH at loci on four other chro-
mosomes (1, 11, 16, 17) in only 5% of cases [20].
Scholes at al. reported LOH in 63% of tumors, the
majority involving chromosome 3 (52%) [21]. Accord-
ing to these authors, the second most common alteration
(21%) was LOH at 13q14 and at 13q12.3-q13 – an RB1
intragenic marker, with retention of a more centromeric
13q marker (near BRCA2). In our material LOH was
found in 7 out of 16 cases (44%), most frequently at
13q22-q31 (24%), which corresponds with the latter
findings. Chromosome 6p is reported the most fre-
quently to display LOH in patients with cervical carci-
noma [22-24]. Other most common sites of LOH are 3p,
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Table 2. Distribution of LOH over the fifteen STR loci in all investigated cancer types.
11q, 17p, 18q. LOH was frequently found at 3p21.1
(41%) [24]. About 40% of squamous cell carcinoma of
uterine cervix displayed LOH at 11q23.3 and 11q22
[25,26]. On chromosome 17p13.3 LOH was found in
about 35% of specimens [24,25]. Kozlowski et al.
demonstrated LOH in 75% cases of squamous cell car-
cinoma G2 and G3 [27]. According to these authors,
eight of nine cervical cancers (83.3%) in clinical stage
III showed LOH. In these samples LOH was also pres-
ent on two or three other chromosomes (3p, 11p, 12p,
18q and 21q). In our material LOH was detected in 60%
of cases with cervical cancers. Few studies have inves-
tigated the loss of heterozygosity and microsatellite
instability in soft tissue sarcomas. Taubert et al. ana-
lyzed samples of human soft tissue sarcomas to deter-
mine the status of the chromosomal region 12q14-15,
which contains the MDM2 gene encoding the well-
known counterpart of the tumor suppressor p53 [28]. Of
the 88 soft tissue sarcoma samples, 24 (27%) showed
evidence of LOH at markers representing 12q14-15,
and 12 (14%) showed evidence of MSI. According to
these authors, the alterations occur early in soft tissue
sarcoma progression and possibly define a subgroup of
soft tissue sarcoma. In the material analyzed here, we
found no evidence of LOH at the chromosomal region
12p12pter which contains intron 40 of the human von
Willebrand factor gene, associated with the endothelial
structure [29]. In the present study the changes were dis-
tributed over fourteen out of fifteen STRs analysed, but
the most affected were D3S1358 and D18S51. This
prevalence is in line with the comprehensive results
from 118 solid tumors, 46 lymph node metastases, and
16 distant metastases analysed with the AmpFlSTR Pro-
filer by Poetsch et al. [30]. The presented data as well as
reports of other authors suggest that genetic instability
resulting from defective human DNA mismatch repair
mechanism in human carcinomas may cause interpreta-
tion difficulty during forensic genotyping and DNA pro-
file matching [31-33]. We suggest that during genotyp-
ing human DNA extracted from histopathological tissue
sections caution should be taken when non-match or
exclusion based on few discrepancies is concluded. 
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